Medinice S.A.

Regulatory Filings • Aug 8, 2023

The Management Board of Medinice S.A. (the _quot;Company_quot;) announces thatrecently it signed an agreement with BioStat sp. z o.o. for CRO[Contract Research Organization] services related to the clinical trialfor the CoolCryo_#174; project. The Agreement meets the criteria ofsignificant contracts due to its importance for the further developmentof the CoolCryo_#174; product and is an important element of theimplementation of the _quot;Company's Project Schedule for 2023-2025_quot;, whichthe Company announced in current report ESPI 12/2023 on 20 April 2023.

The subject of the Agreement is the preparation and conduct of aclinical trial for the CoolCryo_#174; system. Services under the Agreementwill include, but are not limited to, clinical trial administration,monitoring, efficacy and safety testing, and study site management. Theterms of the contract do not differ from those commonly used for thistype of contract. The total value of the contract will depend on thefinal number of medical procedures performed and the completion date ofthe study.

CoolCryo_#174; is an atrial fibrillation treatment system that uses liquidnitrogen to perform cardiac cryoablation. The use of the CoolCryo_#174;cryoablation system in cardiac surgery contributes to greater efficiencyby achieving the lowest cooling temperature, resulting in shorterprocedure times, reduced procedure costs and shorter hospitalisation andrehabilitation.